A Modified-Delphi Consensus on the Management of Patients with FLT3-Mutated AML - PubMed
3 hours ago
- #consensus recommendations
- #FLT3-mutated AML
- #FLT3 inhibitors
- FLT3 inhibitors (FLT3i) have transformed the treatment of FLT3-mutated Acute Myeloid Leukemia (AML).
- A modified Delphi consensus process was used to develop evidence-based recommendations for FLT3-mutated AML management.
- Diagnostic testing should include analysis for both FLT3-ITD and FLT3-TKD mutations, using capillary electrophoresis or NGS.
- Fit patients should receive intensive chemotherapy plus a FLT3i (midostaurin or quizartinib) and be evaluated for allo-HSCT.
- For unfit patients, the current standard of HMA + venetoclax is considered suboptimal, necessitating alternative strategies.
- MRD monitoring is recommended to assess relapse risk and optimize allo-HSCT strategy.
- In relapsed/refractory (R/R) settings, retesting FLT3 status is mandatory, with gilteritinib as the standard treatment.
- FLT3i integration has shifted FLT3m-AML into a more favorable intermediate prognostic category, enhancing the role of curative strategies like allo-HSCT.